Global Pediatric Health (Aug 2021)

The Outcome of Children With Malignant Bone Tumors: A Single-Center Experience

  • Mohammadreza Bordbar MD,
  • Ali Sarfaraz MD,
  • Sezaneh Haghpanah MD, MPH,
  • Omidreza Zekavat MD,
  • Soheila Zareifar MD,
  • Tahereh Zarei MS

DOI
https://doi.org/10.1177/2333794X211042238
Journal volume & issue
Vol. 8

Abstract

Read online

Malignant bone tumors (MBT) account for 3% to 5% of cancers in children younger than 15 years. We aimed to report the outcome of children with MBT in 10 years in Southern Iran. During the study period, 100 patients (57 Osteosarcoma, 43 Ewing sarcoma) with an M/F ratio of 1.56 and a median age of 13.8 years (3.8-17.9) were diagnosed. Metastasis occurred in 27% of patients, mostly in the first 3 months of diagnosis. The mean survival time of MBT altogether was 94.1 months (95% CI: 86.5-101.7). The 5-year overall survival and event-free survivals were 85.2% (95% CI: 74%-91.8%) and 69.2% (95% CI: 56%-79%), respectively. Metastasis was the only independent risk factor of death in our study cohort (Hazard ratio 36.7, 95% CI: 4.8-282.6, P = .001) MBT in children mostly occur in adolescent boys. About one-third of them become metastatic, which is significantly associated with poor outcomes.